Recent News Releases

All business units will incorporate CSL name and branding to signify one company MELBOURNE, Australia, Aug. 10, 2022 /PRNewswire/ -- Global biotech leader CSL today announced that all business...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR All regulatory clearances received for the acquisition of Vifor Pharma AG Settlement of the offer is scheduled for 9 August 2022 Seasoned biopharma...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Melbourne, Australia, and St. Gallen, Switzerland, 13 July 2022 – CSL Limited (ASX: CSL; USOTC:CSLLY) today announced an update regarding the Vifor...

Seqirus – a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), – has entered into a multi-year influenza research partnership with the University of Liverpool Pandemic Institute. Under the partnership, Seqirus will participate in research projects and knowledge generation around both the threat of seasonal influenza and the development of innovative approaches to pandemic preparedness and response.

CSL continues to provide medicines to patients around the world. 24 Jun 2022 Safeguarding our people, patients and donors remains our top priority. As the COVID-19 pandemic evolves, CSL continues...